Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...

Over the past year, "progress" in drug development started to look very different. AI moved beyond pilots into day-to-day execution, while protocols, regulatory expectations, and budgets grew more ...

Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition ...

Q4 2025 Management View CEO Paul LaViolette stated that Pulse Biosciences is “creating a pulsed field ablation platform to completely shift how physicians treat disease” by advancing nanosecond pulsed ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

Company reports encouraging monotherapy expansion data in platinum-resistant ovarian cancer and initiates first combination study with standard-of-care chemotherapies in Q1 2026 Timothy Bowler, M.D., ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...